The Academy of Managed Care Pharmacy (AMCP) Format for Formulary Submissions is the standard framework used by pharmaceutical and biotechnology manufacturers to communicate clinical and economic evidence to U.S. healthcare decision-makers (HCDMs). Formally updated to Version 5.0, the format reflects the growing complexity of medical products, the integration of digital health, and an increased regulatory focus on health equity and real-world evidence.
For market-access, medical-writing, and health economics and outcomes research (HEOR) teams, the AMCP dossier is not a promotional brochure; it is a source-cited scientific document designed to answer a payer’s critical question: What is the clinical and economic value of this product to our member population? This guide outlines the core structure of the Version 5.0 format, details the major updates, and provides a checklist for developing a high-quality submission.
The core structure of the Version 5.0 dossier
The standard AMCP dossier is organized into six distinct sections, designed to move a payer reviewer from a high-level value summary to detailed clinical and economic evidence.
┌──────────────────────────────────────────────────────────┐
│ AMCP Version 5.0 Dossier Structure │
├──────────────────────────────────────────────────────────┤
│ Section 1: Executive Summary of Clinical & Economic Value │
├──────────────────────────────────────────────────────────┤
│ Section 2: Product Information & Disease Description │
├──────────────────────────────────────────────────────────┤
│ Section 3: Clinical Evidence (Trials & RWE) │
├──────────────────────────────────────────────────────────┤
│ Section 4: Economic Value & Modeling Report │
├──────────────────────────────────────────────────────────┤
│ Section 5: Additional Supporting Evidence (PROs, etc.) │
├──────────────────────────────────────────────────────────┤
│ Section 6: Supporting Information & Appendices │
└──────────────────────────────────────────────────────────┘
- Section 1: Executive Summary: A concise overview of the product’s clinical efficacy, safety profile, economic value proposition, and place in therapy. Payers frequently cite this section as the most critical for initial formulary triage.
- Section 2: Product Information and Disease Description: Contains FDA-approved labeling, NDC numbers, dosing, administration, and a description of the target disease state, including prevalence and unmet clinical needs.
- Section 3: Clinical Evidence: The backbone of the dossier. It contains detailed summaries of pivotal clinical trials, including study designs, endpoints, patient demographics, and statistical readouts.
- Section 4: Economic Value and Modeling Report: Describes the budget impact models (BIM) and cost-effectiveness analyses (CEA) available to payers, detailing input assumptions, time horizons, and sensitivity analyses.
- Section 5: Additional Supporting Evidence: Summarizes patient-reported outcomes (PROs), usability and adherence studies, and companion diagnostic requirements.
- Section 6: Supporting Information: Contains references, appendices, and contact information for the manufacturer's medical affairs team.
Key updates in AMCP Version 5.0
Version 5.0 introduced four major updates to address the evolving clinical and technological landscape of biopharma:
1. Digital Therapeutics (DTx) Integration
The format now includes specific guidance for prescription digital therapeutics. Manufacturers of DTx products must provide details on software compatibility, system integration, data security (HIPAA compliance), user-engagement metrics, and device usability. Payers require this information to assess how a DTx product fits into digital formulary frameworks.
2. Health Disparities and Health Equity
Version 5.0 recommends that manufacturers describe social and demographic disparities associated with the target disease state. Dossiers should include subgroup analyses highlighting how the therapy performs in historically underrepresented populations and address barriers to access. Payers use this data to design targeted clinical programs and address health equity within their member populations.
3. Real-World Evidence (RWE) Guidelines
Payers place a high value on real-world outcomes that supplement randomized clinical trials (RCTs). The updated format provides structured guidance on integrating RWE—such as observational studies, registry data, and retrospective claims analyses—particularly to demonstrate long-term safety, real-world adherence, and product value in diverse patient populations.
4. Preapproval Information Exchange (PIE) Alignment
Following the regulatory codification of the PIE Act, Version 5.0 clarifies how manufacturers can share pre-approval information with payers. Dossiers can now include structured pre-approval sections detailing ongoing Phase 3 trial designs, expected approval timelines, and projected patient volume, allowing payers to plan formulary budgets prior to the formal FDA approval date.
Dossier development best practices
To ensure a dossier is well-received by PBM and health plan formulary committees, manufacturers should adhere to several operational guidelines:
- Maintain a Strict Non-Promotional Tone: The dossier is a medical document. Avoid marketing language, unsupported comparative claims, or sales graphics. Every clinical assertion must be linked to a peer-reviewed publication or FDA review document.
- Treat the Dossier as a Living Document: Do not archive the dossier after launch. It must be updated regularly as new data emerges, including new FDA-approved indications, updated clinical guidelines, post-marketing safety warnings (such as the recent CGRP class warnings), or new RWE publications.
- Observe Unsolicited Request Protocols: In compliance with FDA regulations, proactive distribution of a post-approval AMCP dossier is restricted. Manufacturers should generally provide the dossier only in response to an unsolicited request from a healthcare decision-maker, documenting the request for compliance records.
- Emphasize Brevity and Formatting: Payer reviewers have limited time. Prioritize tables, summaries, and hyperlinked references over long narrative blocks. A concise, well-structured dossier is significantly more effective than a dense, 200-page document.
Sources
- Academy of Managed Care Pharmacy (AMCP), "The AMCP Format for Formulary Submissions, Version 5.0," April 2024. https://www.amcp.org/format
- Journal of Managed Care & Specialty Pharmacy (JMCP), "Guidance for the Presentation of Clinical and Economic Evidence: The AMCP Format Version 5.0," 2024. https://www.jmcp.org/
- U.S. Food and Drug Administration (FDA), "Drug Products Under Development: Preapproval Information Exchange (PIE) Guidance for Industry," June 2018. https://www.fda.gov/media/113662/download
- ISPOR (International Society for Pharmacoeconomics and Outcomes Research), "The Role of AMCP Dossiers in Payer Decision-Making and Formulary Submissions," 2024. https://www.ispor.org/
